Trials / Completed
CompletedNCT01118754
Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
Phase I/II Prospective, Randomized, Double Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Compared to Placebo for the Treatment of Dry Eye Disease
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 132 (estimated)
- Sponsor
- Santen Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate if DE-101 ophthalmic suspension will safely and effectively improve signs and or symptoms of dry eye disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DE-101 ophthalmic suspension | Ophthalmic suspention; QID |
| DRUG | DE-101 ophthalmic suspension | Ophthalmic suspension; QID |
| DRUG | DE-101 ophthalmic suspension vehicle | ophthalmic suspension vehicle; QID |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2010-05-07
- Last updated
- 2011-11-03
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01118754. Inclusion in this directory is not an endorsement.